BioSpace News Archive

Fujitsu’s Quantum-Inspired Digital Annealer technology applied to drug discovery process to streamline the search for candidate compounds

Germany-based Evotec is partnering with Japan’s Takeda Pharmaceutical to develop at least five drug discovery programs across a broad range of indications.

Inclisiran is the first and only drug for cholesterol in the siRNA class.

The U.S. Food and Drug Administration cleared Abbott’s blood test to help aid in the diagnosis of heart attacks for men and women hours earlier than standard tests and marks significant progress for detecting heart attacks in women.

Immutep Limited announces that it will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.

Clinigen Group plc, the global pharmaceuticals and services group, has published its full year results for the year ended 30 June 2019.

Phase 3 TITAN is the first registrational study to achieve statistical significance in dual primary endpoints of overall survival and radiographic progression-free survival in patients with mCSPC regardless of extent of disease

TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, reduced toxicity and decreased dosing frequency

Immutep Limited announces that it will receive a milestone payment from GSK of GBP 4 million related to the the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.

Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP), part of the of the European Medicines Agency (EMA), recommended an update to marketing authorizations of approved interferon beta treatments, including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), to remove pregnancy contraindications and, where clinically needed, to allow use during pregnancy and breastfeeding in women with relapsing multiple sclerosis (MS).